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ARTICLE
A large CRISPR-induced bystander mutation causes
immune dysregulation
Dimitre R. Simeonov 1,2,3,4, Alexander J. Brandt4,5, Alice Y. Chan3,6, Jessica T. Cortez1,2,3,4, Zhongmei Li2,3,4,
Jonathan M. Woo2,3,4, Youjin Lee2,3,4, Claudia M.B. Carvalho7, Alyssa C. Indart1, Theodore L. Roth1,2,3,4,5,
James Zou 8,9, Andrew P. May9, James R. Lupski7, Mark S. Anderson3, F. William Buaas10,
Daniel S. Rokhsar4,11,12 & Alexander Marson2,3,4,9,13,14
A persistent concern with CRISPR-Cas9 gene editing has been the potential to generate
mutations at off-target genomic sites. While CRISPR-engineering mice to delete a ~360 bp
intronic enhancer, here we discovered a founder line that had marked immune dysregulation
caused by a 24 kb tandem duplication of the sequence adjacent to the on-target deletion.
Our results suggest unintended repair of on-target genomic cuts can cause pathogenic
“bystander” mutations that escape detection by routine targeted genotyping assays.
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CRISPR-Cas9 genome engineering is employed widely togenerate targeted in vitro and in vivo genetic modifica-tions1. The Cas9 nuclease can be programmed to target
specific genome sequences via a short guide RNA. Although
unintended genome alterations have been mitigated by recent
technical advances2–6, they remain a concern, especially for
therapeutic applications of CRISPR. To date, attention has been
focused on “off-target” editing in which Cas9 nuclease activity is
directed towards genomic sites, other than the target, with
varying degrees of homology to the guide RNA. Here we
demonstrate that “bystander” mutations—unintended mutations
neighboring the “on-target” cut site—must also be considered.
Results
CRISPR-Cas9 deletion of Il2ra enhancer. One advantage of
genome editing over RNA knock-down approaches is that non-
coding sequences can be modified, which enables studies of non-
coding variants commonly associated with human disease risk.
We recently identified a conserved autoimmunity-associated
IL2RA intronic enhancer that controls the timing of gene
expression in response to T-cell stimulation7. To study its in vivo
function, we used CRISPR to engineer non-obese diabetic (NOD)
mice with deletion of this enhancer (EDEL). We successfully
generated EDEL founder lines by targeting Cas9 to cut on
either side of the ~360-bp enhancer (Fig. 1a). Genomic PCR and
targeted Sanger sequencing confirmed that approximately
360–370 bp was deleted at the enhancer site in multiple founders
(Fig. 1b, Supplementary Figure 1). Three of the founders were
backcrossed to wild-type NOD animals at least one generation
before breeding the enhancer deletion to homozygosity for
experimentation.
Surprisingly, immunophenotyping revealed a marked systemic
difference in one line of mice. Unlike the other two characterized
lines, homozygous EDEL progeny from the third founder line had
hallmark features of a lymphoproliferative disorder, including
variable splenomegaly, increased cellularity and higher percen-
tages of memory T cells (Figs. 1c, d and Supplementary Figure 1).
Despite the phenotypic differences among the lines, the on-target
enhancer deletion only differed by a few nucleotides at the
margins of the deletion (Supplementary Figure 1). The evolutio-
narily conserved DNA sequence at the site was deleted in all
three lines and the line with more severe phenotype had a slightly
smaller deletion, suggesting that the genotyped sequence
differences directly at the deletion site did not explain observed
differences in immune regulation (Supplementary Figure 1). The
more severe immune phenotype persisted in progeny with the
enhancer deletion from the affected line, even after an additional
round of backcrossing and multiple generations of breeding,
suggesting a mutation in close genomic proximity to the on-target
deletion site rather than an unlinked off-target effect. Taken
together, our data suggested the presence of an additional
mutation linked to the Il2ra enhancer deletion in this immune
dysregulated founder line (IDFL).
To determine the molecular and cellular effects of the linked
mutation in the IDFL mice, we analyzed IL2RA expression.
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Fig. 1 Immune dysregulation in a founder line of CRISPR-engineered Il2ra enhancer deletion mice. a CRISPR-engineered Il2ra enhancer deletion (EDEL)
founder lines that were bred for immunophenotyping. b Genomic DNA PCR to genotype the Il2ra enhancer deletion in animals from Line 2 and the immune
dysregulated founder line (IDFL). c Representative CD44 surface staining on CD4+ T cells isolated from spleens of wild-type (WT) and EDEL mice
from different founder lines. d Quantification of percent CD44+ cells from (c) (Lines 1 and 2: WT n= 8, EDEL n= 7; IDFL: WT n= 8, EDEL n= 7).
e Representative induction of IL2RA surface expression on naive CD4+ T cells (CD4+IL2RA-CD44–) activated with anti-CD3/CD28 antibodies.
f Quantification of percent IL2RA+ cells from (e) (Line 2: WT n= 4, EDEL n= 4; IDFL: WT n= 4, EDEL n= 4). g Representative IL2RA surface expression
on FOXP3+CD4+T cells (Tregs) from spleen of different founders. h Quantification of normalized percent IL2RA- cells of CD4+FOXP3+ Tregs from (g)
(Lines 1 and 2: WT n= 10, EDEL n= 10; IDFL: WT n= 3, EDEL n= 3). Panels (d) and (h) include data from Lines 1 and 2 animals previously published7.
All data are presented as mean ±s.d. and are representative of at least two independent experiments. ****P≤ 0.001 by two-way analysis of variance
(ANOVA) with Dunnett’s multiple comparisons test. Raw gel image corresponding to b is shown in Supplementary Figure 7
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Double-negative (DN) thymocytes from IDFL mice had marked
loss of IL2RA expression, whereas DN thymocytes from the other
lines of EDEL mice had normal IL2RA expression (Supplemen-
tary Figure 1). Mature CD4+ effector T cells (Teffs) normally
upregulate IL2RA to their surface after activation. Strikingly,
in vitro stimulated IDFL Teffs largely failed to express IL2RA on
their surface (Figs. 1e, f and Supplementary Figure 2). This was in
contrast to the other EDEL lines, which showed delayed but not
ablated induction of IL2RA following stimulation of naive
T cells7. We also examined FOXP3+ regulatory T cells (Tregs),
which constitutively express high levels of IL2RA and require it
for their survival. Across lymphoid tissues there was an increased
percentage of FOXP3+IL2RA– Tregs in IDFL mice compared
with other EDEL lines (Figs. 1g, h and Supplementary Figure 2).
In vitro and in vivo regulatory T-cell differentiation were
impaired (Supplementary Figure 3). Interestingly, a subset of
T cells, including some Tregs, did express high levels of IL2RA.
An Il2ra null mutation would be expected to ablate expression
across cell types. Instead, we find that the linked mutation has
effects on IL2RA expression that vary among cells, with a subset
of T cells selectively maintaining IL2RA expression.
Identification of a bystander mutation. To identify the mutation
causing marked immune dysregulation, we sequenced the whole
genomes of EDEL mice from the IDFL and from one of the
other founder lines (Fig. 2a). We looked for a causative IDFL
mutation both at the IL2ra locus and throughout the genome.
Consistent with the observed genetic linkage with the enhancer
deletion, we discovered a large structural mutation in the Il2ra
locus that was unique to the IDFL genome. Careful analysis of
the read pileups revealed a 24-kb block of DNA with elevated
coverage in the IDFL genome compared with adjacent sequences,
consistent with an increase in copy number (Fig. 2a). Paired-end
reads at the breakpoint implied a tandem duplication, which
we confirmed by genomic PCR and Sanger sequencing (Fig. 2b).
The duplicated sequence starts immediately downstream of
the deleted Il2ra enhancer and spans the remainder of the first
intron, the second Il2ra exon and most of the second intron.
This unexpected structural mutation tightly linked to the inten-
ded on-target edit is a “bystander” mutation that causes marked
immune dysregulation.
We next interrogated how the duplication formed. Previous
work showed that paired CRISPR-induced DNA breaks can result
in tandem duplication of the intervening sequence8,9, however,
no predicted off-target cutting sequences were identified in the
Il2ra locus to explain this duplication event (Supplementary
Figure 4). Although we cannot rule out spontaneous DNA breaks
from DNA replication, our data suggest that the duplication
is more likely an unintended product of repair from on-target
editing. Sequence homology could contribute to a duplication
event. We did not find extended sequence homology between
the cut site and the duplication junction, but we did discover
microhomology at the breakpoint junction (Supplementary
Figure 4). However, three nucleotides of microhomology are
found commonly in the genome, raising a question of why this
distal site may have been used for repair. Chromatin looping can
bring distal genomic sites into close proximity. Indeed, published
high-resolution chromatin conformation capture data suggested
three-dimensional proximity between the Il2ra enhancer and
the site of the duplication junction (Supplementary Figure 4)10,
although the statistical significance of this putative looping
interaction was not determined. We then tested whether
microhomology and looping were sufficient to drive recurrent
duplications at this site (Supplementary Figure 4). We repeated
CRISPR microinjections into single-cell NOD/ShiLtJ zygotes,
cultured them in vitro and analyzed > 50 blastocysts and failed to
observe the recurrence of this particular duplication event despite
efficient deletion (~80%) of the enhancer at the on-target site.
Note, there were two blastocysts with PCR bands of roughly the
expected duplication size, but the sequence could not be
confirmed. Taken together, our analysis of the duplication is
consistent with a complex unintended repair consequence that
occurs much less frequently than the intended enhancer deletion.
The duplication of exon 2 is predicted to generate a novel splice
junction that would result in a premature stop codon in the Il2ra
mRNA (Fig. 2c). Although the expected effect of the homozygous
duplication would be to ablate protein expression in every cell,
we were nevertheless able to detect CD4+ T cells with near
normal levels of IL2RA expression. To understand how these
cells expressed IL2RA despite the predicted premature stop codon
generated by the duplication, we performed RNA-seq on IL2RA+
T cells from spleen. As expected, we could identify reads with
the aberrant exon 2–exon 2 splice junction only in the IFDL
EDEL cells (Fig. 2c and Supplementary Figure 5). However,
IL2RA+ IDFL cells had ~10-fold more reads that contained
the wild-type exon 2–exon 3 junction than the aberrant exon
2–exon 2 junction (Fig. 2c). PCR and Sanger sequencing of
Il2ra complementary DNA (cDNA) confirmed that these cells
predominantly generate Il2ra transcript with a single exon 2
between exons 1 and 3 (Supplementary Figure 5). In contrast,
we did not detect transcripts with a single exon 2 in IL2RA–
T cells induced to express Il2ra (Supplementary Figure 5). These
isoform differences suggest that some T cells, including a subset
of Foxp3+ Tregs, are able to correctly splice the aberrant Il2ra
genetic structure and productively translate IL2RA.
Discussion
This report links a CRISPR-induced bystander mutation to
in vivo pathology. We build on previous work that showed
CRISPR editing can cause bystander deletions and complex
rearrangements in neighboring on-target sequences11. Further
work is needed to understand the frequency with which such
mutations occur, as well as the DNA repair rules that underlie
these events. Identification of the bystander mutation depended
on having multiple independent founder pedigrees to demon-
strate an aberrant phenotype in one line and genetically link
it to the on-target edit. New methods and analytical tools are
needed to detect both unintended CRISPR-induced bystander
and off-target mutations. Genome engineering not only allows
gene knockout, but also permits targeted alterations of non-
coding cis-regulatory sequences for mechanistic study of human
variants and for cell therapies. The bystander mutation allele
observed here was introduced by murine zygote editing by Cas9
mRNA and gRNA microinjection. The marked immune pheno-
type was revealed by breeding the rare allele to homozygosity.
The functional consequences, if any, of rare unintended alleles
in a population of human primary somatic cells edited by various
CRISPR delivery strategies remain largely untested. Bystander
editing effects—which can be easily missed with conventional
genotyping methods—must be carefully assessed for research and
clinical CRISPR applications, especially for mounting therapeutic
efforts to fine tune gene regulatory programs.
Methods
Mouse generation. Il2ra enhancer deletion (EDEL) mice were generated by the
Jackson Laboratory (Bar Harbor, ME, USA) by microinjection of gRNA and Cas9
mRNA. Briefly, Cas9 mRNA (100 ng µl−1) and mIL-2Ra-CaRE4 gRNAs (50 ng µl
−1) were mixed and injected into NOD/ShiLtJ zygotes. Four founders with the
enhancer deletion were identified by PCR amplicon size and confirmed by
sequencing of TOPO-cloned PCR products. We immunophenotyped three founder
lines. The EDEL mouse lines were established by backcrossing founders for at least
one generation before breeding to homozygosity. Protospacer sequence for gRNAs
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used in the production of the founder lines in this study are in Supplementary
Data 1.
Mouse genotyping. The enhancer deletion was initially genotyped in all founders
by Sanger sequencing genomic DNA from proteinase K digested tail tissue. PCR
amplification of the CaRE4 enhancer was carried out using HotStart Taq (Bioline
USA Inc.) and primers (mIl2ra-EDEL-F, mIl2ra-EDEL-R) that span the edited site.
PCR amplicons were then sequenced with the mIl2ra-EDEL-F primer. Primer
sequences in Supplementary Data 1. The duplication junction was confirmed by
PCR amplification of the junction followed by gel electrophoresis and Sanger
sequencing. The primers used are in Supplementary Data 1.
Mouse experiments and data analysis. All mice were maintained in the UCSF-
specific pathogen-free animal facility in accordance with guidelines established by
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Fig. 2 Identifying a large tandem duplication in the Il2ra locus. a Read pileups at the Il2ra locus from genome sequencing of a homozygous enhancer
deletion (EDEL) mouse (Line 2) and homozygous and heterozygous EDEL mice from the immune dysregulated founder line (IDFL). Red lines were added to
highlight the elevated read counts in IDFL mice. b Schematic of the Il2ra locus with the large tandem duplication in IDFL mice. PCR and Sanger sequencing
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the Institutional Animal Care and Use Committee and Laboratory Animal
Resource Center. Experiments were done with animals aged between 1 and
4 months. Wild-type littermate mice were used as controls for all immunophe-
notyping experiments. All mice used in this study were normoglycemic. No data
were excluded from analysis. Power calculations were not performed and data
were assumed to be normally distributed. Experiments were done without
blinding or randomization. All data are derived from at least two independent
experiments unless otherwise stated. Both male and female mice were used for
experiments.
Mouse immunophenotyping. Briefly, cells from spleen, peripheral lymph nodes
(peri-LNs), and thymus were collected from each mouse. Spleen, peri-LNs, and
thymus were dissociated in 1× phosphate-buffered saline (PBS) with 2% fetal
bovine serum (FBS) and 1 mM EDTA. The mixture was then passed through a
70-μm filter. Ammonium-chloride-potassium lysis buffer was used to deplete red
blood cells from splenocytes. All antibody stains were performed at a 1:100 dilution
in 30–50 μl of 1× PBS. To pellet the cells, centrifugation was performed at 300 g
for 5 min. For immunophenotyping, approximately 2 million cells were stained
per tissue sample. Cells were first stained with a viability dye at a 1:1000 dilution
in 1× PBS for 20 min at 4 °C, then washed with EasySep Buffer (1× PBS, 2% FBS,
1 mM EDTA). Cells were then resuspended in the appropriate surface staining
antibody cocktail and incubated for 30 min at 4 °C, then washed with 1× PBS. Cells
were then fixed, permeabilized, and stained for transcription factors using the
Foxp3 staining kit (eBioscience) according to the manufacturer’s instructions.
Antibody staining panels are listed in Supplementary Data 1.
IL2RA induction on stimulated naive T cells. Naive T cells were isolated from
spleen and lymph nodes with CD4+ negative selection (Stemcell Technologies)
followed by fluorescence-activated cell sorting for CD4+IL-2Ra−CD44−. In all,
100,000 cells were activated per well of a 96-well plate coated with 2 μg ml−1 anti-
CD3 and anti-CD28. Cell analysis by flow cytometry was performed every day
for 3 days.
In vitro Treg differentiation. Spleens were dissociated in EasySep Buffer and
splenocytes were enriched for CD4+ T cells using the Mouse CD4 Negative
Selection Kit as described above. Naive CD4+ CD62L+ CD44– T cells were
sorted. In all, 100,000 cells were stimulated with plate bound anti-CD3/CD28
antibodies in a 96-well plate in the presence of 2 ng/ml TGF-b (Miltenyi Biotec)
and 200 U/ml IL2 (Miltenyi Biotec) for 3 days. Treg differentiation was assessed
by surface staining for IL2RA and intracellular staining for Foxp3 without a
viability dye.
Genome sequencing sample preparation. DNA was isolated from kidney tissue
by phenol–chloroform extraction. PCR-free whole-genome libraries were con-
structed by the Genome Technologies Core at The Jackson Laboratory using the
KAPA Hyper Prep Kit (KAPA Biosystems), targeting an insert size of 400 base
pairs. Libraries were checked for quality and concentration using the Bioanalyzer
High Sensitivity DNA Assay (Agilent), Qubit dsDNA BR Assay (ThermoFisher),
and quantitative PCR (KAPA Biosystems), according to the manufacturer's
instructions. Libraries were sequenced at Novogene, 150-bp paired-end on the
HiSeq X (Illumina) to a target mean coverage depth of 30 × .
Genome sequencing alignment and variant calls. Bwa mem was used for
alignment to the mouse mm10 reference sequence. Reads at the identified tandem
duplication junctions were then assembled using Velvet12 in order to confirm the
exact base pair sequence, as well as assist in picking primers for confirmation of the
duplication via PCR. The Picard Software Suite and GATK 4.0 pipeline13 with
default settings was used for variant analysis. Base recalibration was performed
with NOD-specific variants, both single nucleotide polymorphisms (SNPs) and
insertions and deletions (INDELs), obtained from the Wellcome Sanger Institute
Mouse Genome Project.
CRISPR off-target analysis. We first performed a biased off-target analysis
looking for variants 5 bp on either side of predicted off-target cut sites. This was
done for the top 49 predicted off-target sites for each gRNA that was used to make
the enhancer deletion mouse lines. In total, six variants were found with this
analysis, all of which were present in the NOD background variant panel. We also
performed an unbiased variant analysis to examine potentially confounding
mutations that fit a likely inheritance model. The cohort variant call file was subset
for biallelic SNPs and INDELs where all individuals were assigned a genotype with
a sufficient average coverage ( >= 10 reads). Variants were unique or in excess in
the immune dysregulated mouse as compared with the other two mice in the
cohort. The resulting alleles were further subset by removing NOD-specific SNP
and INDEL variants and selecting only variants that fell within exonic regions. This
revealed 2407 variants. The remaining variants are likely specific to the NOD mice
used to generate our founder lines. Other than the 24-kb duplication, we found
no coding or splicing mutations near the enhancer deletion that might contribute
to the observed phenotypes. Identifiers GT_05102 and GT_05105 refer to
heterozygous and homozygous EDEL mice from the IDFL founder line. GT05111
is homozygous EDEL mouse from Line 2. Finally, we performed computational
prediction of off-target cutting for the Il2ra enhancer gRNAs throughout the
Il2ra gene body (Supplementary Figure 4).
RNA sequencing. Briefly, approximately 500,000 CD4+ IL2RA+ cells were sor-
ted from CD4-enriched splenocytes and total RNA was isolated from samples using
the RNeasy Micro Kit (QIAGEN) according to the manufacturer’s instructions
with the following options: cells were pelleted and resuspended in RLT buffer with
β-mercaptoethanol and homogenized using QIAshredder (QIAGEN). DNA
removal was performed with gDNA Eliminator Columns (QIAGEN). RNA sam-
ples were analyzed with a NanoDrop spectrophotometer and all samples had a 260/
280 ratio of 1.80 or higher. RNA integrity was measured by Bioanalyzer and all
samples had an RNA integrity score (RIN) of 8.0 or more. RNA-seq libraries were
prepared by the Functional Genomics Laboratory at Berkeley. RNA samples were
poly-A selected and then converted into sequencing libraries with the ultra-low
input SMART-seq kit. The samples were pooled and sequenced on one lane of
the Illumina HiSeq4000. Il2ra isoform analysis was done using the UNIX grep
command to identify reads in raw fastq that contained sequences for the E2–E2
junction (ACCAGCAACTAACTGTGTCT) or E2–E3 junction (ACCAGCAACT
CCCATGACAA). Read counts were normalized to the total number of reads for a
given sample. Short reads were also aligned with STAR to the mouse mm10
reference. Differential expression analysis was performed using EdgeR from Bio-
conductor Package for R14.
Il2ra cDNA isoform analysis. In all, 500,000 IL2RA+ (CD4+IL2RA+) and
IL2RA– (CD4+IL2RA+CD44–) CD4+ T cells were sorted from CD4-enriched
splenocytes. IL2RA– CD4+ T cells were stimulated in vitro for 10 h with 2 μg ml–1
plate-bound anti-CD3/CD28 antibodies (Biolegend). In total, 430,000 DN thy-
mocytes (Live CD45+CD4–CD8–) were sorted from thymus. RNA was extracted
using the RNA Micro Kit (QIAGEN) as described above. RNA was reverse tran-
scribed into cDNA using SuperScript VILO MasterMix as per manufacturer’s
protocol (Thermo Scientific). PCR of the cDNA to assess exon 2 splicing was
performed with forward and reverse primers that sit in Il2ra exon 1 and exon 3,
respectively (Supplementary Data 1). PCR was carried out with Bioline Taq 2x
MasterMix as per manufacturer’s protocol. Amplicons were cut out of the agarose
gel and purified using QIAGEN’s Gel Extraction Kit. Amplicons were sequenced
in the forward and reverse directions using the primers from the initial PCR
amplification.
Zygote Il2ra enhancer editing. NOD/ShiLtJ zygotes were microinjected with
gRNAs and Cas9 mRNA, matching the generation of Il2ra EDEL mice. PCR
amplification and Sanger sequencing were used to check gDNA for the duplication
junction and WT Il2ra sequence upstream of Il2ra exon 3, the genomic site of the
IDFL duplication junction (Supplementary Figure 4). Blastocyst gDNA was also
checked for on-target enhancer deletion by PCR amplification and Sanger
sequencing (Supplementary Figure 4). A second test for the duplication junction
was performed using a nested PCR. Briefly, duplication junction PCR samples were
diluted (1 μl sample in 10 μl water) and 1 μl of dilution was used as the template. A
nonspecific band was observed in a majority of the blastocysts (data not shown).
Nine amplicons were extracted and sent for Sanger sequencing, of which six were
successfully sequenced. The primers used for these assays are listed in Supple-
mentary Data 1. The reconstructed sequences are assembled in Supplementary
Figure 6. Takara PrimeSTAR polymerase was used for amplification with 30-s
extension for 35 cycles. PCR products were run on agarose gel for size separation
and visualization.
Data analysis. The statistical tests and sample sizes used for data analysis are
included in figure legends.
Illustrations. Images in Fig. 1a (mice) and Supplementary Figure 4 (scissors) were
created with BioRender.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Whole-genome sequencing and RNA sequencing data have been uploaded to NCBI
Sequencing Read Archive (SRA Accession: PRJNA510427). These data were used to
generate Figs. 2a, c. Additional raw data used to generate the main figures are available
in Supplementary Data 2. Any other relevant data in this manuscript will be made
available upon request.
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